Inhibrx Biosciences Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022
Period Ending	Aug '25 Aug 14, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Market Capitalization	340	223	-	-
Enterprise Value	261	28	-	-
Last Close Price	23.57	15.40	-	-
PE Ratio	-	0.13	-	-
PS Ratio	260.48	1114.65	-	-
PB Ratio	4.98	1.67	-	-
P/TBV Ratio	4.97	1.67	-	-
EV/Sales Ratio	186.53	142.16	-	-
Debt / Equity Ratio	1.56	0.06	4.83	-0.69
Asset Turnover	0.01	0.00	0.01	-
Inventory Turnover	-	34.28	35.84	-
Quick Ratio	4.82	3.76	4.95	0.01
Current Ratio	4.98	3.94	5.25	0.30
Return on Equity (ROE)	-113.71%	1905.92%	-1333.38%	-
Return on Assets (ROA)	-26.29%	-67.38%	-84.42%	-
Return on Capital (ROIC)	-31.17%	-83.29%	-108.99%	-
Earnings Yield	-48.02%	757.00%	-	-
FCF Yield	-34.44%	-88.37%	-	-
Buyback Yield / Dilution	-15.09%	-27.17%	-	-

Updated Aug 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q